

Our Ref: 568/2023  
November 2023

## Re: Your request made under the Freedom of Information Act 2000

Please see below a Freedom of Information request made by OPEN Health. Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.

### Patients with acute myeloid leukaemia (AML)

1. How many patients with AML, in total, have been treated with the following therapies during the last 6 months, irrespective of start date or line of therapy?
  - Azacitidine monotherapy
  - Low dose cytarabine (LoDAC) monotherapy
  - Venetoclax + azacitidine
  - Venetoclax + LoDAC
  - Ivosidenib
  - Intensive chemotherapy-based regimen
  - Other

Answer:

2. How many newly diagnosed patients with AML have started first-line treatment with the following therapies during the last 6 months?
  - Azacitidine monotherapy
  - Low dose cytarabine (LoDAC) monotherapy
  - Venetoclax + azacitidine
  - Venetoclax + LoDAC
  - Ivosidenib
  - Intensive chemotherapy-based regimen
  - Other

Note: this should only include patients who have started first-line treatment during the 6-month window

Answer:

3. (a) Of the patients with AML treated with venetoclax (venetoclax + azacitidine or venetoclax + LoDAC) in the last 6 months, how many are approved for treatment via Blueteq?

Answer:

### Patients with chronic lymphocytic leukaemia (CLL)

4. How many patients with CLL have received treatment with venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include patients who started treatment prior to the 6-month window

Answer:

5. How many patients with CLL who were new to all lines of treatment received venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include only patients who have started treatment during the 6-month window

Answer:

- Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

Our Ref: 568/2023  
November 2023